Agilent Technologies (A) Stock Declining After Earnings Miss

NEW YORK (TheStreet) -- Shares of Agilent Technologies Inc (A) are declining, lower by 1.24% to $42.10 in early market trading Tuesday following the company's second quarter earnings results, released after the closing bell yesterday.

The measurement company earned 38 cents per share for the quarter, missing the consensus estimate of 39 cents per share, according to analysts polled by Thomson Reuters.

Revenue came in at $963 million for the second quarter, missing the $989.30 million analysts were expecting.

Looking ahead, the company expects third quarter fiscal year 2015 earnings of between 38 cents to 42 cents per share on revenue of between $995 million to $1.015 billion.

Analysts surveyed by Thomson Reuters expect third quarter fiscal year 2015 earnings of 42 cents per share on revenue of $1 billion.

For fiscal year 2015, Agilent sees earnings of between $1.67 to $1.73 per share on revenue of between $4.05 billion to $4.11 billion.

Analysts surveyed by Thomson Reuters expect fiscal year 2015 earnings of $1.69 per share on revenue of $4.068 billion.

Santa Clara, Calif.-based Agilent Technologies provides core bio-analytical and electronic measurement solutions to the life sciences, diagnostics and genomics, chemical analysis, communications and electronics industries.

Separately, TheStreet Ratings team rates AGILENT TECHNOLOGIES INC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate AGILENT TECHNOLOGIES INC (A) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income."

If you liked this article you might like

What a Difference a Day Makes for New SEC Rule

Jim Cramer: Agilent Technology Has Been One of My Favorites

Jim Cramer -- Agilent Is 'Continuing to Defy Gravity'

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis